4.7 Article

Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies

Journal

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Volume 26, Issue 9, Pages 2213-2221

Publisher

AMER SOC NEPHROLOGY
DOI: 10.1681/ASN.2014010093

Keywords

-

Funding

  1. German Federal Ministry for Education and Research [BMBF01EO1004]
  2. German ministry for education and research [01ZX1313AKroed]
  3. European Union [LSHM-CT-2004-503485, 201668, 305739]
  4. INTERREG IV Oberrhein Program [A28]
  5. European Regional Development Fund
  6. Wissenschaftsoffensive TMO
  7. Medical Faculty of the University of Wurzburg
  8. Netherlands Heart Foundation [2007T046]
  9. Netherlands Organization for Scientific Research (NWO VIDI) [917.13.350]

Ask authors/readers for more resources

Galectin-3 has been linked to incident renal disease, experimental renal fibrosis, and nephropathy. However, the association among galectin-3, renal function, and adverse outcomes has not been described. We studied this association in two large cohorts of patients over a broad range of renal function. We measured galectin-3 concentrations in baseline samples from the German Diabetes mellitus Dialysis (4D) study (1168 dialysis patients with type 2 diabetes mellitus) and the Ludwigshafen Risk and Cardiovascular Health (LURIC) study (2579 patients with coronary angiograms). Patients were stratified into three groups: eGFR of >= 90 ml/min per 1.73 m2, 60-89 ml/min per 1.73 m(2), and <60 ml/min per 1.73 m(2). We correlated galectin-3 concentrations with demographic, clinical, and biochemical parameters. The association of galectin-3 with clinical end points was assessed by Cox proportional hazards regression within 10 years (LURIC) or 4 years (4D) of follow-up. Mean +/- SD galectin-3 concentrations were 12.8 4.0 ng/ml (eGFR90 ml/min per 1.73 m2), 15.6 5.4 ng/ml (eGFR 60-89 ml/min per 1.73 m(2)), 23.1 9.9 ng/ml (eGFR<60 ml/min per 1.73 m(2)), and 54.1 19.6 ng/ml (dialysis patients of the 4D study). Galectin-3 concentration was significantly associated with clinical end points in participants with impaired kidney function, but not in participants with normal kidney function. Per SD increase in log-transformed galectin-3 concentration, the risks of all-cause mortality, cardiovascular mortality, and fatal infection increased significantly. In dialysis patients, galectin-3 was associated with the combined end point of cardiovascular events. In conclusion, galectin-3 concentrations increased with progressive renal impairment and independently associated with cardiovascular end points, infections, and all-cause death in patients with impaired renal function.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available